SNY vs. TAK: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at SNY and TAK, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
Both SNY and TAK are American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies.
| Symbol | SNY | TAK |
|---|---|---|
| Company Name | Sanofi | Takeda Pharmaceutical Company Limited |
| Country | France | Japan |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 121.27 billion USD | 46.76 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | July 1, 2002 | January 5, 2010 |
| Security Type | ADR | ADR |
Historical Performance
This chart compares the performance of SNY and TAK by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | SNY | TAK |
|---|---|---|
| 5-Day Price Return | 9.88% | -3.16% |
| 13-Week Price Return | 3.29% | -0.96% |
| 26-Week Price Return | -16.42% | -4.96% |
| 52-Week Price Return | -15.55% | 5.51% |
| Month-to-Date Return | 8.44% | -2.40% |
| Year-to-Date Return | -9.13% | 3.21% |
| 10-Day Avg. Volume | 2.37M | 4.99M |
| 3-Month Avg. Volume | 2.01M | 4.26M |
| 3-Month Volatility | 32.89% | 18.65% |
| Beta | 0.91 | 0.38 |
Profitability
Return on Equity (TTM)
SNY
14.92%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
SNY’s Return on Equity of 14.92% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
TAK
1.95%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
TAK’s Return on Equity of 1.95% is in the lower quartile for the Pharmaceuticals industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
Net Profit Margin (TTM)
SNY
20.51%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
A Net Profit Margin of 20.51% places SNY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
TAK
3.06%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
Falling into the lower quartile for the Pharmaceuticals industry, TAK’s Net Profit Margin of 3.06% indicates weaker profitability. This means the company retains a smaller portion of each dollar in sales as profit compared to its competitors.
Operating Profit Margin (TTM)
SNY
19.08%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
SNY’s Operating Profit Margin of 19.08% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
TAK
8.05%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
TAK’s Operating Profit Margin of 8.05% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | SNY | TAK |
|---|---|---|
| Return on Equity (TTM) | 14.92% | 1.95% |
| Return on Assets (TTM) | 8.49% | 0.95% |
| Net Profit Margin (TTM) | 20.51% | 3.06% |
| Operating Profit Margin (TTM) | 19.08% | 8.05% |
| Gross Profit Margin (TTM) | 71.85% | 64.78% |
Financial Strength
Current Ratio (MRQ)
SNY
1.27
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
SNY’s Current Ratio of 1.27 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
TAK
1.16
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
TAK’s Current Ratio of 1.16 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
SNY
0.32
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
SNY’s Debt-to-Equity Ratio of 0.32 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
TAK
0.66
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
TAK’s Debt-to-Equity Ratio of 0.66 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
SNY
22.06
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
SNY’s Interest Coverage Ratio of 22.06 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
TAK
1.96
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
In the lower quartile for the Pharmaceuticals industry, TAK’s Interest Coverage Ratio of 1.96 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | SNY | TAK |
|---|---|---|
| Current Ratio (MRQ) | 1.27 | 1.16 |
| Quick Ratio (MRQ) | 0.94 | 0.59 |
| Debt-to-Equity Ratio (MRQ) | 0.32 | 0.66 |
| Interest Coverage Ratio (TTM) | 22.06 | 1.96 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
SNY
5.02%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
With a Dividend Yield of 5.02%, SNY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
TAK
4.53%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
With a Dividend Yield of 4.53%, TAK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
SNY
52.56%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
SNY’s Dividend Payout Ratio of 52.56% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
TAK
124.94%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
TAK’s Dividend Payout Ratio of 124.94% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | SNY | TAK |
|---|---|---|
| Dividend Yield (TTM) | 5.02% | 4.53% |
| Dividend Payout Ratio (TTM) | 52.56% | 124.94% |
Valuation
Price-to-Earnings Ratio (TTM)
SNY
8.69
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
In the lower quartile for the Pharmaceuticals industry, SNY’s P/E Ratio of 8.69 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
TAK
49.95
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
At 49.95, TAK’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
Price-to-Sales Ratio (TTM)
SNY
1.78
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
SNY’s P/S Ratio of 1.78 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
TAK
1.53
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
In the lower quartile for the Pharmaceuticals industry, TAK’s P/S Ratio of 1.53 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
SNY
1.44
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
SNY’s P/B Ratio of 1.44 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
TAK
1.03
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
TAK’s P/B Ratio of 1.03 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | SNY | TAK |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 8.69 | 49.95 |
| Price-to-Sales Ratio (TTM) | 1.78 | 1.53 |
| Price-to-Book Ratio (MRQ) | 1.44 | 1.03 |
| Price-to-Free Cash Flow Ratio (TTM) | 9.51 | 8.36 |